6
Dec 22
IRCCS reform: Upcoming changes with regard to research
The regulation of Scientific Institutes for Research, Hospitalization, and Health Care (“Istituti di Ricovero e Cura a Carattere Scientifico,” “IRCCS” or “Institutes”) is undergoing a major transformation in Italy.
5
Dec 22
The European Commission sends a Statement of Objection to a drug manufacturer accusing it of regulatory gaming and denigration of competitors in breach of Article 102 TFEU
On October 10, 2022, the European Commission sent a Statement of Objection to Teva accusing the company of denigrating a competing product and of “regulatory gaming” in management of the life cycle of its multiple sclerosis drug Capoxone, conduct deemed abusive pursuant to Article 102 of the Treaty on the Functioning of the European Union.
5
Dec 22
Medical and scientific communication on the web: New IFPMA-EFPIA guidelines
On September 28, two international associations representing the pharmaceutical industries, the IFPMA and the EFPIA, published a joint Note for Guidance on social media and digital channels that offers guidance for pharmaceutical companies using the web to provide doctors and patients with information about their products and the diseases they are intended to treat.
5
Dec 22
The National Recovery and Resilience Plan, Mission No. 6, “Health”: Current status
In recent months, implementation of the measures contained in Mission No. 6 of the National Recovery and Resilience Plan, which allocates over 15 billion euro to the health sector, has come to the fore with the adoption of a series of actions that outline more specifically the contents of the two macro-areas of intervention, the “components” of the mission.
